Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;197(3):320-325.
doi: 10.1111/bjh.18090. Epub 2022 Mar 14.

Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study

Dale Jobson  1   2 , Christopher J McCormack  1 , Victoria Mar  2   3 , Constantine Tam  4   5 , Michael A Henderson  1   6
Affiliations

Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study

Dale Jobson et al. Br J Haematol. 2022 May.

Abstract

With new, effective treatments for chronic lymphocytic leukaemia (CLL) the impact of second malignancies is increasingly important. We performed a retrospective case-controlled study examining the effect of CLL and its treatment on melanoma-specific survival and recurrence. A total of 56 patients with melanoma with CLL were matched 1:1 to patients without CLL for age, date of diagnosis, gender and melanoma tumour, node, metastasis (TNM) stage. Multivariate analysis found CLL was associated with significantly worse melanoma-specific mortality (hazard ratio [HR] 2.46, 95% confidence interval [CI] 1.27-4.74, p = 0.007) and recurrence (HR 3.44, 95% CI 1.79-6.63, p < 0.001). Patients with CLL had poor immunotherapy tolerance and prior CLL treatment was not associated with melanoma outcomes.

Keywords: chronic lymphocytic leukaemia; melanoma; recurrence; survival; treatment.

PubMed Disclaimer

Conflict of interest statement

Constantine Tam has an honorarium and research funding from Janssen, Abbvie and Beigene. Victoria Mar has received honoraria from Merck, Novartis and Bristol‐Myers‐Squib and research funding from MoleMap.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier survival curves of (A) melanoma‐specific survival (MSS) and (B) recurrence‐free survival (RFS) in patients with melanoma with CLL compared to no CLL. Log‐rank comparison between CLL and no CLL groups for MSS and RFS were significantly worse in the CLL group (p = 0.004 and p = 0.0002 respectively). (C) Cumulative incidence plot of melanoma recurrence with death from non‐melanoma related cause as competing risk in both CLL and no CLL groups. Grey’s test found a statistically significant difference in melanoma recurrence between the CLL and no CLL group (p = 0.0005), but not for death from other causes (p = 0.70) [Colour figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Karimkhani C, Green AC, Nijsten T, Weinstock M, Dellavalle RP, Naghavi M, et al. The global burden of melanoma: results from the global burden of disease study 2015. Br J Dermatol. 2017;177:134–40. - PMC - PubMed
    1. Mulcahy A, Mulligan SP, Shumack SP. Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59:578–82. - PubMed
    1. Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992;84:1422–7. - PubMed
    1. Brewer JD, Shanafelt TD, Otley CC, Roenigk RK, Cerhan JR, Kay NE, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population‐based study. J Clin Oncol. 2012;30:843–9. - PubMed
    1. Whitman ED, Bustami R. Survival for melanoma patients with pre‐existing chronic lymphocytic leukemia. J Clin Oncol. 2012;30(Suppl):e19057.

Publication types